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Abstract 
 
    The 5-HT2A receptor (5-HT2AR) is implicated in psychotropic changes within the 
central nervous system (CNS). A number of polymorphisms have been reported in 
the 5-HT2AR gene; one of these results in a non-synonymous change, H452Y, in the 
carboxy-terminal tail of the receptor protein. The minor allele (9% occurrence) has 
been statistically associated with CNS dysfunction such as impaired memory 
processing and resistance to neuroleptic treatment in schizophrenic patients. We 
investigated the impact of H452Y mutation of the 5-HT2AR expressed in COS7 cells 
on distinctly coupled intracellular signalling pathways from the receptor, focusing on 
the heterotrimeric G protein-independent phospholipase D (PLD) pathway, compared 
to the conventional Gq/11-linked phospholipase C (PLC) pathway. The H452Y 
mutation selectively attenuated PLD signalling, which as in the wild-type receptor, 
was mediated by a molecular complex involving PLD1 docked to the receptor’s 
carboxy-terminal tail domain. Co-immunoprecipitation and GST-fusion protein 
experiments revealed that the H452Y mutation selectively reduced PLD1 binding to 
the receptor. Experiments with blocking peptides to mimic short sections of the 5-
HT2AR tail sequence revealed that the peptide spanning residue 452 strongly 
reduced PLD but not PLC responses of the receptor. Similar observations were 
made when assessing both PLD responses and PLD-dependent cellular proliferation 
elicited by activation of 5-HT2ARs natively expressed in MCF-7 cells. Overall these 
findings indicate that the H452Y polymorphic variant of the 5-HT2AR displays 
selective disruption of its PLD signalling pathway. This may potentially play a role in 
the CNS dysfunction associated with the H452Y allele of the 5-HT2AR. 
 
 
 
 
Keywords 
 
5-HT2A receptor; signalling; phospholipase D; phospholipase C; polymorphism; 
H452Y 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   3	  
 
 
1. Introduction 
 
    The 5-HT2A receptor (5-HT2AR) is the likely site of action of a number of 
hallucinogenic drugs and is thought to be an important target of atypical antipsychotic 
agents, acting as antagonists [1]. In addition to its conventional signalling through 
Gq/11 to activate phospholipase C (PLC) [2], the 5-HT2AR can activate a variety of 
other signalling pathways [3-9]. There is increasing evidence that the 5-HT2AR can 
also activate phospholipase D (PLD) through small G protein-dependent pathways 
that may be independent of heterotrimeric G proteins [10, 11]. The 5-HT2AR can 
activate PLD through a molecular complex in which both ARF1 and PLD1 are bound 
at distinct sites within the receptor’s carboxy-terminal domain [11, 12]. In different cell 
models, the closely related 5-HT2CR can activate PLD through a G13 / Rho - 
dependant pathway [13]. In the ARF1 / PLD1 - dependant model system investigated 
here, the binding site for PLD1 has been localised to the distal 33 amino acids of the 
receptor’s carboxy-terminal tail (residues 439-471) [12]. 
    Interestingly the human 5-HT2AR gene presents a number of single nucleotide 
polymorphisms within the coding region, several of which are non-synonymous, for 
example the H452Y variant (minor allele frequency 9 %; [14, 15]) where the 
sequence change falls within the region we have identified as the PLD binding site.  
The H452Y allele has been statistically associated with resistance to the atypical 
antipsychotics clozapine and olanzapine in schizophrenic patients [16-19], as well as 
with deficits in memory, novel information processing and neurodevelopment of 
temporal structures [20-24], with bipolar disorder [25, 26] and perhaps with attention-
deficit hyperactivity disorder (ADHD) [27].  There is some evidence that the 
conventional PLC / Ca2+ mobilisation pathway of 5-HT2AR intracellular signalling may 
be modified in the H452Y variant [28-30], although other studies did not observe 
statistically significant alterations in receptor-mediated Ca2+ responses [31, 32]. It has 
been suggested that the H452Y variant 5-HT2AR may exist in a preferentially 
desensitised state with respect to PLC signalling and correspondingly displays 
reduced levels of 5-HT-stimulated [35S]GTP-γS binding to pertussis toxin-sensitive 
and-insensitive G proteins [29]. A modest attenuation of PLD signalling was also 
seen in these experiments, but under conditions where the 5-HT2CR at least utilises a 
G13 / Rho -dependant  pathway of activation. In addition the H452Y polymorphism 
may attenuate 5-HT2AR homodimerisation and heterodimerisation with the D2R, 
although the functional significance of this is not yet clear [33]. 
    In the present study (primarily utilising a cell model system where the 5-HT2AR 
activates the PLD pathway through an ARF1 / PLD1 complex assembled around its 
carboxy-terminal tail), we asked whether mutation of residue 452 from the wild-type 
histidine (H) to the variant tyrosine (Y) form differentially impacts on PLD compared 
to PLC signalling by the receptor. 
 
2. Material and methods 
 
2.1. Biochemical reagents 
 
    All chemicals were obtained from Sigma-Aldrich, unless otherwise indicated. The 
selective 5-HT2AR agonist (R)-DOI and antagonist M100709 [34] were obtained from 
RBI-Sigma and Axon Medchem respectively. The selective PLD1 and PLD2 
inhibitors VU 0155069 (CAY 10593) and VU 0359595 and the selective PLD2 
inhibitor BML 280, which are reported to show 163 fold, 1700 and 21 fold selectivity 
for their preferred targets in cellular assays [35-37] were obtained from Cayman 
Chemicals, Avanti Polar Lipids and Enzo Life Sciences respectively. The N-
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myristoylated peptides were synthesised by Insight Biotechnology Ltd. Radiolabelled 
chemicals were obtained from Perkin-Elmer. 
 
2.2. Cell culture and transfection 
 
    COS7 cells or MCF-7 cells (kindly provided by Nick Morley, University of 
Edinburgh) were maintained in culture in Dulbecco's modified minimum essential 
medium (DMEM; Sigma) containing 10 % normal or foetal calf serum, respectively 
(Harlan) and 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen). Cells were 
seeded into 12-well plates (for PLD and PLC assays) or flasks (for ligand binding, co-
immunoprecipitation and glutathione S-transferase (GST)-fusion protein studies) and 
allowed to reach ~ 60 % confluency (after ~ 24 h) before transfer to medium 
containing defined serum substitute Ultroser G (Pall Biosepra). Transfections were 
carried out using FuGENE 6 (Roche Applied Science). Cells were used 72 h after 
seeding. 
 
2.3. Plasmids and mutagenesis 
 
    The Protein C epitope-tagged human 5-HT2AR construct was described previously 
[11]; haemagglutinin (HA) epitope-tagged ARF1-HA was kindly provided by Julie 
Donaldson, NIH; HA epitope-tagged PLD1 and catalytically inactive mutants HA-
[K898R]PLD1 and HA-[K758R]PLD2 were kindly provided by Mike Frohman, Stony 
Brook University; [Q209L/D277N]Gαq was obtained from the Missouri S & T cDNA 
Resource Centre and [T19N]RhoA was kindly provided by Gary Bokoch (The Scripps 
Institute). cDNAs for PrC-[H452Y]5-HT2AR and GST-[H452Y]5-HT2ARct(376-471) 
were generated from their wild-type equivalents using the Becton-Dickinson 
Transformer method for in vitro site-directed mutagenesis. In brief, the parent 
plasmid was denatured to yield two single stranded parent plasmids and incubated 
with a mutagenic and a selection primer (with a mutation in a restriction enzyme site). 
The two primers were simultaneously annealed to the single stranded DNA, and 
following elongation, ligated with T4 DNA ligase. Selected mutated and control 
plasmids were transformed into mutS Escherichia Coli (E.Coli) strains (defective in 
mismatch repair) and DNA from the pooled bacterial population was isolated. 
Mutated plasmids were isolated based on the selection primer’s resistance to a 
restriction enzyme. The mutated DNA was then transformed into bacterial cells. 
Constructs were confirmed by sequencing of both strands. 
 
2.4. PLC and PLD assays 
 
    PLC and PLD activation was measured by radiotracer assays for [3H]inositol 
phosphate ([3H]InsP) production in the presence of 10 mM LiCl and [3H]phosphatidyl 
butanol ([3H]PtdBut) production in the presence of 30 mM butan-1-ol, as described 
previously [10-12, 38]. Standard PLC and PLD assays were carried out over 60 min 
and 10 min respectively unless otherwise indicated and normally with a 5-HT or (R)-
DOI concentration of 3 µM, although 5-HT concentrations from 0.3 nM - 3 µM were 
used in some experiments. For experiments assessing desensitisation, time-courses 
of 5-HT-evoked PLC and PLD responses were measured at 6 time points over 0-60 
min or 0-15 min respectively.  
 
2.5. GST-fusion protein studies 
 
    GST-5-HT2AR-ct(376-471), GST-[H452Y]-5-HT2ARct(376-471) constructs or empty 
vector were transformed into BL21-RIL bacterial cells, which were then grown up in 
standard 2x yeast extract/ tryptone/NaCl medium with 2 % glucose as described 
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previously [11, 12]. Fusion protein expression was induced by 0.5 mM isopropyl-β-D-
thiogalactoside (3 h, 37 °C; Invitrogen).  Cells were harvested by centrifugation and 
lysed with BugBuster reagent (Merck Chemicals Ltd.) and centrifuged (12,000 g, 25 
min, 4 °C). The supernatant was then incubated for 30 min at room temperature with 
Glutathione-Sepharose 4B beads (GE Healthcare; 100 µl beads with 1:100 protease 
inhibitor cocktail set III (PI; Calbiochem)/1 ml supernatant), and the matrix was 
washed extensively with phosphate-buffered saline (PBS). To prepare ARF1-HA and 
HA-PLD1-enriched cellular extracts, transfected cells were homogenised or lysed 
respectively in ARF buffer (PBS with 1 mM dithiothreitol, 1 mM sodium 
orthovanadate, 1:100 PI) or PLD buffer (20 mM HEPES, 150 mM NaCl buffer 
containing 20 % glycerol, 1 % CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulphonate), 1 % sodium deoxycholate, 1 mM sodium orthovanadate, 1:100 
PI). The washed GST-fusion protein-bead complexes were then incubated overnight 
(4 °C, with rotation) with ARF1-HA or HA-PLD1 extracts or control buffer and PBS. 
Beads were then washed twice in ice-cold buffer A (PBS containing 20 % glycerol, 1 
% CHAPS, 1 % sodium deoxycholate, 0.5 mM EDTA) with 1:100 PI, followed by 
three washes with diluted buffer A (1:20 in PBS; 1:100 PI). Retained proteins were 
solubilised in 50 µl Laemmli buffer (2 % sodium dodecyl sulphate, 5 % 
mercaptoethanol, 20 mM Tris-HCl pH 7.4). 
 
2.6. Immunoprecipitation and Western blots 
 
    Transfected COS7 cells were deprived of serum substitute for 4 h and washed with 
Hanks' balanced salt solution (10 ml; Invitrogen), prior to the addition of IP buffer 
(HEPES 20 mM pH 7.5, NaCl 150 mM, 20 % glycerol, 1 % CHAPS, 0.5 % sodium 
deoxycholate, 1 mM sodium orthovanadate and 1:100 PI; 1 ml/75 cm2 flask). After 45 
min on ice, extracts were centrifuged at 12,000 g (15 min, 4 °C) and the supernatants 
were pre-cleared with Protein G-Sepharose 4B beads (Sigma; 20 µl of 1:1 
suspension in IP buffer; incubation: 45 min, 4 °C, with rotation). Samples were then 
incubated with primary antibodies, as described previously [11, 12]: (mouse anti-
Protein C tag; PrC; HPC4, Roche Applied Bioscience or mouse non-immune IgG; NI-
IgG; Sigma) and 20 µl/ml Protein G-Sepharose 4B suspension before incubation 
overnight at 4 °C, with rotation. Beads were collected by centrifugation and washed 
three times with IP buffer prior to the addition of Laemmli buffer (40 µl/ml of original 
supernatant). 
    Using the NuPAGE Surelock Mini-cell system (Invitrogen), samples and aliquots of 
original lysate supernatents from immunoprecipitation and GST studies were run on 
4 - 12 % Bis-Tris gels, which were subsequently blotted onto polyvinylidene fluoride 
membrane (Immobilon-PSQ; Millipore). Detection antibodies in GST studies were: 
goat anti-GST (GE Healthcare) used with horseradish peroxidase (HRP)-conjugated 
donkey anti-goat/sheep IgG (Millipore) and HRP-linked rat anti-HA (3F10). For co-
immunoprecipitation studies, detection antibodies were the HRP-linked rat 
monoclonal anti-HA (3F10; Roche Applied Science) and mouse anti-PrC (HPC4) 
together with HRP-conjugated donkey anti-mouse secondary (Millipore). The binding 
of HRP-linked antibodies to membranes was detected by enhanced 
chemiluminescence using LumiGLO (Cell Signaling Technology). Densitometric grey 
scale measurements from scanned films were made using Image-J (NIH). 
  
2.7. Ligand binding and cell surface biotinylation 
 
    After removal of the serum substitute for 4 h, cells were harvested in ice cold 
ketanserin binding buffer (50 mM Tris, 5 mM MgCl2, 1 mM EGTA; pH 7.2 with 1:100 
PI and disrupted with an Ystral homogeniser [11, 12, 38]. Homogenates were 
centrifuged (10 min, 2000 g, 4 oC), to pellet nuclear debris. The supernatants were 
further centrifuged (30 min, 12,000 g, 4 oC) to pellet microsomal membranes, which 
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were washed before resuspension by trituration. Membranes were incubated with 0.8 
nM [3H]ketanserin (72.2 Ci/mmol) and a range of concentrations of unlabelled 
ketanserin (0.1-300 nM) for homologous displacement, or 10 µM mianserin to 
determine non-specific binding (60 min, 37 oC). Binding was quenched with ice-cold 
buffer and membranes pelleted by centrifugation (20 min, 12,000 g, 4 oC). The 
supernatant was aspirated and [3H]ketanserin bound to the pellet was measured by 
scintillation counting. Non-linear curve fitting was used to derive Kd and Bmax values. 
Protein concentrations were determined using the Pierce BCA Protein Assay Kit.  
    Cell surface biotinylation was carried out using a membrane-impermeant covalent 
agent (biotinamidocaproic acid 3-sulpho-N-hydroxysuccinimide ester; NHS-sulfo-
biotin) and the capture of solubilised biotinylated proteins on (reversibly binding) 
monomeric avidin agarose beads as described previously [12]. Biotinylated proteins 
were eluted using 2 mM biotin in solubilisation buffer. Total and biotinylated receptor 
levels were assessed by incubating aliquots of lysate and avidin agarose eluate 
respectively with 0.8 nM [3H]ketanserin alone or with 10 µM mianserin to determine 
non-specific binding. Binding was terminated by protein precipitation through the 
addition of 18 % polyethylene glycol-8000 in PBS at 4 oC with 0.003 % bovine γ-
globulin as a carrier. After vigorous vortexing, tubes were kept on ice for 15 min 
before centrifugation (20 min, 12,000 g, 4 oC). [3H]ketanserin associated with the 
pellets was measured by scintillation counting.  
 
2.8 Measurement of cell proliferation using Alamar Blue 
  
    MCF-7 cells were aliquoted into 48-well plates in DMEM containing 0.5% foetal 
calf serum and penicillin/streptomycin at a density of 30,000 cells/cm2 and incubated 
for 24 h to fully adhere. (R)-DOI (3 µM) was added to activate 5-HT2AR signalling and 
control wells received only corresponding vehicle. 5-HT2AR antagonist and small 
molecule or peptide blockers of signalling were added as appropriate immediately 
prior to agonist. Incubation was continued for 48 h at 37oC in 5% CO2 atmosphere 
before Alamar Blue solution (Invitrogen) was added to one tenth of the assay volume 
according to the manufacturer’s instructions. After 2 h, fluorescence was measured 
at excitation 560 nm, emission 590 nm in a fluorometric plate reader. Alamar Blue 
contains non-fluorescent resazurin, which is converted to bright red-fluorescent 
resorufin via the reduction reactions of metabolically active cells. The amount of 
fluorescence produced is proportional to living cell number, so the assay can be used 
to monitor cell proliferation induced by added stimuli (in this case, the selective 5-
HT2AR agonist, (R)-DOI). 
 
2.9. Data analysis 
 
    Data are presented as mean values ± the standard error of the mean (SEM) from 
n separate experiments, as indicated. Where appropriate, data were analysed by 
non-linear regression (GraphPad Prism 4). The statistical significance of differences 
was determined by ANOVA, t-tests or Mann-Whitney U-tests as appropriate, with p < 
0.05 used as the criterion for significance. 
 
3. Results 
 
3.1. Comparison of PLC and PLD signalling by the 5-HT2AR and the [H452Y]5-HT2AR 
 
    As PLD signalling by the 5-HT2AR involves PLD1 physically associated with the 
distal part of the receptor’s carboxy-terminal tail, within the span of residues 439-471 
[12], we asked whether the H452Y polymorphic form of the receptor might display 
prominent alterations in PLD signalling compared to its conventional PLC pathway, 
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coupled through Gq interaction with the third intracellular loop [39]. COS7 cells 
transiently transfected with the PrC-5-HT2AR or the PrC-[H452Y]5-HT2AR, expressed 
similar numbers of specific [3H]ketanserin binding sites in the post-nuclear membrane 
fraction, with similar KD values as determined by homologous displacement (Table 
1A). In addition, the proportion of specific [3H]ketanserin binding sites that could be 
recovered from monomeric avidin beads after cell surface biotinylation and lysis was 
similar between PrC-5-HT2AR- and PrC-[H452Y]5-HT2AR-transfected cells (Table 
1B). Thus there appeared to be no marked difference in ligand binding properties or 
plasma membrane localisation between the two receptor forms. Standard protocol 
assays for PLC (3 µM 5-HT, 60 min) or PLD (3 µM 5-HT, 10 min) on COS7 cells 
transfected with PrC-5-HT2AR or PrC-[H452Y]5-HT2AR showed significantly reduced 
PLC and PLD responses in the H452Y variant, with PLD responses reduced to a 
greater extent; 49% reduction, p=0.0044, compared to PLC responses; 23% 
reduction, p=0.0422 (Fig. 1A). Earlier studies on Ca2+ mobilisation in platelets and 
PLC responses in transfected NIH3T3 or HEK293 cells indicated attenuation or 
greater desensitisation of responses in the H452Y variant receptor [28-30]. The 
relatively modest attenuation of PLC responses seen here in the H452Y variant 
receptor may relate to the low levels of endogenous arrestin and GRK expression in 
COS7 cells [40]. When desensitisation of PLC responses was assessed in terms of 
the time course of [3H]InsP production in response to 3 µM 5-HT, both the PrC-5-
HT2AR and the PrC-[H452Y]5-HT2AR showed a gradual reduction in the rate of 
activity over 0-60 min. Although no statistically significant difference could be 
detected in the behaviour of the wild type and H452Y variant receptors (Fig.1B), PLC 
responses of the H452Y variant appeared less than those of the wild-type at longer 
time points, an observation consistent with Fig. 1A and the idea that desensitisation 
of PLD signalling may be greater at the H452Y variant. In contrast, the time-course of 
PLD activation showed a significantly reduced initial rate of [3H]PtdBut production at 
the H452Y variant compared to the wild-type receptor (p<0.05 up to 6 min), (Fig.1D), 
suggesting that the H452Y polymorphism exerts a mechanistically distinct effect on 
PLD signalling from that on PLC signalling. 5-HT (3 µM) did not elicit any discernible 
activation of PLC or PLD in untransfected COS7 cells (Fig.1B,C).  
 
3.2. PLD signalling at both the 5-HT2AR and the [H452Y] variant predominantly 
involves the PLD1 isoform 
 
    Figure 2 shows that the profile of reduction in 5-HT-induced [3H]PtdBut production 
by the wild-type 5-HT2AR due to co-transfection of negative mutant PLD1 but not 
PLD2 or due to a selective PLD1 inhibitor but not a selective PLD2 inhibitor was fully 
reproduced at the H452Y variant. This indicated that the H452Y variant receptor 
utilises a similar pathway of PLD activation as the wild-type 5-HT2A R. As reported 
previously for the wild-type PrC-5-HT2AR [12], [3H]PtdBut responses of the H452Y 
variant were not significantly affected by a dominant negative Gq construct, 
[Q209L/D277N]Gαq, pertussis toxin (200 ng/ml overnight, or a dominant nagtive 
RhoA construct, [T19N]RhoA, showing 84 ± 7, 92 ± 10 and 83 ± 9% of control 
responses respectively (means ± SEM, n=4). These observations are consistent with 
a mechanism of PLD activation independent of Gq/11, Gi/o and G13/RhoA, as seen 
for the wild-type PrC-5-HT2AR under similar conditions. We then assessed the effects 
of co-transfecting additional wild-type PLD1 on [3H]PtdBut production responses of 
the PrC-5-HT2AR and the PrC-[H452Y]5-HT2AR. Figure 3 shows that co-transfection 
of additional wild-type PLD1 increased the concentration-dependent responses to 5-
HT of both the PrC-5-HT2AR and the PrC-[H452Y]5-HT2AR, although the degree of 
amplification of response was markedly greater for the PrC-5-HT2AR compared to the 
H452Y variant. Table 2 documents the mean EC50 and Emax response values from 
non-linear curve fitting of five independent concentration-response curves in each 
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case. No significant differences were detected between EC50 values at the PrC-5-
HT2A R and the PrC-[H452Y]5-HT2A R in the absence or presence of additional 
PLD1. Emax values were significantly greater in the presence of PLD1 for both the 
wild-type and H452Y variant receptors (p<0.01 in each case) but the degree of 
amplification at the PrC-5-HT2AR (3.10 ± 0.26 fold) was significantly greater than at 
the PrC-[H452Y]5-HT2AR (1.72 ± 0.25 fold; p<0.01).  
 
3.3. Physical association of PLD1 with the PrC-[H452Y]5-HT2A R through its carboxy-
terminal tail is reduced compared to the PrC-5-HT2A R 
 
    COS7 cells co-transfected with either the wild-type or H452Y variant receptor, 
together with HA-tagged PLD1 were solubilised and proteins immunoprecipitated 
with PrC-tag antibody or non-immune IgG controls. While both the PrC-5-HT2AR and 
the PrC-[H452Y]5-HT2AR were specifically captured at similar levels, the amount of 
associated HA-PLD1 was clearly and significantly reduced by around 50 % at the 
H452Y variant compared to the wild-type (Fig.4A, Table 3). This was corroborated in 
findings with GST-fusion protein constructs of the carboxy-terminal tail domain of the 
wild-type and H452Y variant receptors (Fig.4B, Table 3). Despite similar input levels 
of GST-fusion protein constructs, the in vitro binding of HA-PLD1 was clearly and 
significantly reduced by around 50 % at the H452Y variant, whereas binding of 
ARF1-HA, which occurs at a more proximal segment of the tail domain [11], was 
unaffected. These observations are consistent with evidence that the critical binding 
region for PLD1 lies between residues 439-471 [12] and highlight residue 452 as 
making an important contribution to the binding site, both in vitro and in a 
physiological cellular context.  
 
3.4. An N-myristoylated blocking peptide spanning residue 452 selectively disrupts 
PLD but not PLC signalling by the PrC-5-HT2AR 
 
    As the PLD1 binding site on the carboxy-terminal tail of the 5-HT2AR falls within the 
distal 33 residues 439-471, we further tested the role in functional PLD signalling of 
the region around residue 452 by designing 3 cell-permeable N-myristoylated decoy 
peptides (replicating residues 439-449, 450-460 and 461-471) and evaluating their 
effects on cellular PLC and PLD responses of the PrC-5-HT2AR in COS7 cells (Fig.5). 
We have previously shown that similar peptides can enter neuronal cells and 
effectively disrupt protein:protein interactions of AMPA receptor subunits [41]. Cells 
were pre-incubated here with the peptides at a concentration of 50 µM for 15 min 
prior to beginning the signalling assays. Neither the 439-449 nor the 461-471 peptide 
had any discernible effect on either PLC or PLD responses. The 450-460 peptide, 
encompassing the region around residue 452, had no effect on PrC-5-HT2AR PLC 
responses but strongly attenuated PLD responses (p<0.01). This corroborates our 
evidence that the region around residue 452 (more specifically residues 450-460) is 
important in PLD1 association and signalling by the 5-HT2A R. The H452Y 
polymorphism in the 5-HT2AR appears to have a physiologically relevant impact 
selectively on the PLD signalling pathway of the receptor by reducing PLD1 
association and activation. 
 
3.5. 5-HT2AR-mediated PLD signalling and cell proliferation in MCF-7 cells are 
selectively blocked by PLD1 inhibitors and an N-myristoylated blocking peptide 
spanning residue 452. 
 
    The 5-HT2AR is natively expressed in native tissues and a number of cell lines 
including MCF-7 breast cancer cells, where it exerts mitogenic effects [42-45]. PLD-
mediated generation of phosphatidic acid plays an important role in the activation of 
mitogenic signalling pathways	  [46, 47] with 5-HT2AR-induced activation of PLD being 
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specifically implicated in mitogenesis in arterial smooth muscle cells	  [45]. We 
therefore investigated 5-HT2AR-mediated PLD signalling and proliferation in MCF-7 
cells to assess whether residues around amino acid 452 in the carboxy-terminal tail 
were necessary in a more physiological context. Firstly we carried out ligand binding 
studies to confirm the presence of 5-HT2AR expression in MCF-7 cells, revealing 
specific [3H]ketanserin binding sites with a Kd of 0.93 ± 0.25 nM and Bmax of 131 ± 28 
fmol/mg membrane protein (mean ± SEM, n=3). We then measured PLD signalling 
responses evoked by the selective 5-HT2AR agonist (R)-DOI in MCF-7 cells. Figure 
6A shows that (R)-DOI (3 µM)-induced [3H]PtdBut production in MCF-7 cells was 
markedly and significantly inhibited by the selective 5-HT2AR antagonist M100907 
(200 nM) and the selective PLD1 inhibitors VU 0155069 (0.5 µM) and VU 0359595 
(50 nM) but not by the selective PLD2 inhibitor BML 280 (5 µM). This confirms the 
presence of native 5-HT2ARs in MCF-7 cells and that they signal through PLD1 rather 
than PLD2, similar to transfected 5-HT2ARs in the COS7 cell model. Figure 6B shows 
that the N-myristoylated decoy peptide mimicking 5-HT2AR residues 450-460 (50 
µM), but not peptides mimicking residues 439-449 or 461-471 significantly inhibited 
(R)-DOI (3 µM)-induced [3H]PtdBut production in MCF-7 cells. Again this matches 
results in transfected COS7 cells, indicating in this more physiological context that 
the region of the 5-HT2AR carboxy-terminal tail around residue 452 is crucial for 
receptor coupling to PLD1. Figure 6C illustrates data on (R)-DOI-induced 
mitogenesis in MCF-7 cells, as measured by the fluorescent reporter of effective 
cellular redox function, Alamar Blue (Invitrogen). The (R)-DOI (3 µM)-induced 
increase in Alamar Blue fluorescence after 48 h growth in DMEM containing 0.5% 
foetal calf serum [44] was significantly inhibited by the 5-HT2AR antagonist M100709 
(200 nM), the PLD1 inhibitor VU 0359595 (50 nM) and the N-myristoylated decoy 
peptide mimicking 5-HT2A R residues 450-460 but not those mimicking residues 439-
449 or 461-471. These observations indicate that native 5-HT2ARs in MCF-7 cells 
appear to signal through PLD1 by a process dependent specifically on residues 450-
460 in the receptor carboxy-terminal tail to mediate the physiological response of 
increased cellular proliferation. 
 
4. Discussion 
 
    The present observations support earlier evidence that 5-HT2AR-mediated Ca2+ 
fluorescence responses were attenuated in platelets of patients heterozygous for the 
H452Y polymorphism [30] and that PLC signalling appeared reduced or preferentially 
desensitised in NIH3T3 or HEK293 cells expressing the H452Y mutant receptor [28, 29]. 
Other reports did not describe such marked effects [31, 32] and the effect on PLC 
signalling we observed was only modest. This may be due to the cell system used here, 
transfected COS7 cells, which contain only low levels of native arrestin and GRK [40] 
and may therefore not display particularly clearly any alternations in desensitisation 
processes. In contrast we observed a robust inhibition of PLD activation at the H452Y 
variant of the 5-HT2AR with a strongly reduced initial rate of 5-HT-induced [3H]PtdBut 
production. Like the wild-type receptor, the H452Y variant appears to use a mechanism 
independent of heterotrimeric G proteins to activate PLD1 but not PLD2 and [3H]PtdBut 
production by both receptor variants is selectively amplified in the presence of additional 
wild-type PLD1. The extent of amplification is however less at the H452Y variant. 
Correspondingly the direct association of PLD1 with the receptor’s carboxy-terminal tail 
domain seen in co-immunoprecipitation and GST-fusion protein binding experiments is 
reduced at the H452Y variant receptor compared to the wild-type. The importance of the 
residues around 452 for PLD docking and signalling was further shown by the selective 
disruption of 5-HT2AR PLD but not PLC signalling by a cell-permeable blocking peptide 
spanning residues 450-460 but not those spanning other sections of the distal tail 
domain.  
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    To evaluate whether similar processes occur in cells natively expressing 5-HT2ARs as 
opposed to the transfected COS7 cell model, we carried out further experiments on 
MCF-7 human breast cancer cells, which express endogenous 5-HT2ARs and respond to 
their activation by increased proliferation [44]. We selected this human cell line rather 
than rodent cell lines or tissues because the distal carboxy-terminal tail of rodent 5-
HT2ARs shows significant divergence from the sequence of the human receptor. MCF-7 
cells were shown to express moderate levels of [3H]ketanserin binding sites and display 
PLD signalling responses to a selective 5-HT2AR agonist that were inhibited by a 
selective 5-HT2AR antagonist, inhibitors of PLD1 but not PLD2 and the myristoylated 
blocking peptides corresponding to 5-HT2AR carboxy-tail residues 450-460 but not 
residues 439-449 or 461-471. Furthermore the physiological response of 5-HT2AR 
agonist-induced MCF-7 cell proliferation was inhibited by these agents with a closely 
parallel profile. The importance of the distal carboxy-terminal tail of the 5-HT2AR for 
PLD1 interaction, PLD signalling and downstream cellular responses was therefore 
confirmed in a more physiological, non-transfected cell context. 
   Overall these findings provide clear evidence for pathway-selective changes in 
signalling by a polymorphic form of the 5-HT2AR that occurs with moderate frequency in 
the population and has been associated in molecular genetics studies with a variety of 
CNS conditions/disorders. While it is possible that such findings may help in validating 
the potential usefulness of pathway-specific therapeutic interventions, the precise impact 
the altered signalling is likely to have on CNS neurons is far from clear. 5-HT2ARs are 
important regulators of pyramidal cell excitability in prefrontal cortex [48]. Altered PLD-
mediated production of phosphatidic acid may impact on a number of downstream 
signalling pathways as well as vesicular trafficking events including exocytosis and 
endocytosis [49] so effects on neuronal excitability are likely to be complex.  
    Factors such as disease phenotypes, environment, treatment and cell type-specific 
regulation of gene expression might potentially also influence allele transcription. It will 
be difficult to ascribe any of the overall psychiatric/neurological deficits associated with 
the H452Y polymorphism in the 5-HT2AR directly to impairment of its PLD signalling.  
Nevertheless the evidence that the H452Y allele is associated with poor clinical 
response in schizophrenic patients to clozapine, which is considered to be the most 
efficacious antipsychotic agent available [50], emphasises the importance of the 5-HT2AR 
(and perhaps its profile of signalling pathway activation) in psychosis.  
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Table 1: Ligand binding to wild-type and H452Y mutant 5-HT2AR constructs 	  
 Specific [3H]ketanserin binding 
PrC-5-HT2AR PrC-[H452Y]5-HT2AR 
a) To total membrane fraction: 
                                              KD (nM) 
                    Bmax (pmol/mg protein) 
 
 
0.58 ± 0.05 
0.90 ± 0.06 
 
 
0.70 ± 0.08 
0.96 ± 0.08 
b) To lysate following cell surface 
biotinylation: 
                   Input lysate (dpm/assay) 
                 Avidin eluate (dpm/assay) 
                              Mean % captured 
 
 
 
 
372 ± 31 
135 ± 32 
36 
 
 
 
336 ± 26 
154 ± 30 
46 
 
A. Affinity and number of binding sites for the selective 5-HT2AR antagonist 
[3H]ketanserin at the PrC-5-HT2AR and the PrC-[H452Y]5-HT2AR were assessed in 
post-nuclear membranes of transfected COS7 cells in the absence/presence of 10 µM 
mianserin, to define non-specific binding. Protein levels were determined using a 
Pierce BCA Protein Assay Kit. A homologous displacement protocol was used 
(unlabelled ketanserin concentrations from 0.1 - 300 nM) with non-linear curve fitting to 
the data from 4 separate determinations. The two 5-HT2AR variants were expressed at 
similar levels and displayed similar affinities for ketanserin. B. Ligand binding to the 
PrC-5-HT2AR and the PrC-[H452Y]5-HT2AR recovered from monomeric avidin beads 
after cell surface biotinylation and solubilisation in a non-denaturing detergent-
containing buffer. [3H]ketanserin binding was measured in the absence/presence of 10 
µM mianserin in 5 separate determinations. The two 5-HT2AR variants showed similar 
proportions of expression at the plasma membrane.  
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Table 2: The effect of additional wild-type PLD1 on the potency and maximal 
effect of 5-HT-induced [3H]PtdBut production responses of the PrC-5-HT2AR and 
the PrC-[H452Y]5-HT2AR 
 
Receptor variant 5-HT-induced [3H]PtdBut production 
EC50 (nM) Emax (fold increase over 
basal) 
Control 
 
+PLD1 
 
mean 
ratio 
control +PLD1 mean 
ratio 
PrC-5-HT2AR 8.7 ± 
1.5 
9.3 ± 
1.7 
1.17 ± 
0.44 
2.45 ± 
0.06 
7.89 ± 
0.34** 
3.10 ± 
0.26†† 
PrC-[H452Y]5-HT2AR 9.3 ± 
1.5 
9.2 ± 
2.0 
1.20 ± 
0.45 
1.59 ± 
0.14 
2.61 ± 
0.19** 
1.72 ± 
0.25 
 
PLD responses to 3 µM 5-HT were measured in COS7 cells transfected with the 
PrC-5-HT2AR or PrC-[H452Y]5-HT2AR and either wild-type HA-PLD1 or (in controls) 
empty vector, pcDNA3.1. Data from 5 concentration-response curves in each case 
were independently fitted by non-linear regression to a sigmoidal dose-response 
model and mean ± SEM values are shown. ** p<0.01, significantly greater than the 
corresponding values in the absence of transfected PLD1 (Mann-Whitney U-test). †† 
p<0.01, significantly greater than corresponding values for the PrC-[H452Y]5-HT2AR 
(Mann-Whitney U-test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   15	  
Table 3: Direct association of HA-PLD1 with wild-type and H452Y mutant 5-
HT2AR constructs. 	  
Assay: Specific association of HA-PLD1 with bait 
(Densitometric grey scale units in excess of NI-
IgG controls (a) or GST alone (b)) 
5-HT2AR [H452Y]5-HT2AR 
a) Co-immunoprecipitation with 
PrC-tagged receptor 
71 ± 17  36 ± 20** 
b) In vitro binding to GST-fusion 
proteins of carboxy-tail constructs 
56 ± 15 29 ± 11* 	  
The capture of HA-PLD1 immunoreactivity associated with (a) PrC-tagged receptor 
immunoprecipitates and (b) GST-fusion protein constructs of the receptor carboxy-
terminal tail was measured by quantitative densitometry of Western Blot films. In a) 
values for wild-type and H452Y mutant 5-HT2AR receptors in excess of control pull-
downs with non-immune IgG were compared (n=4); ** indicates p=0.0027, 
significantly less than wild-type (paired Student’s t-test). In b) values for wild-type and 
H452Y mutant 5-HT2AR carboxy-terminal tail GST-fusion protein constructs in excess 
of GST alone were compared (n=5); * indicates p=0.0188, significantly less than wild-
type (paired Student’s t-test). 
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Figure legends 
 
Fig. 1. Effects of H452Y mutation of the PrC-5-HT2AR on 5-HT-induced PLC and PLD 
responses in transfected COS7 cells. A. In standard protocol assays, 3 µM 5-HT-evoked 
responses were measured (60 min for PLC, 10 min for PLD) in 6 independent 
experiments. Data are displayed as mean ± SEM. Analysis by two-tailed Student’s t-test 
indicated significantly reduced PLC responses (*, p=0.0422) and PLD responses (**, 
p=0.0044) for the H452Y variant compared to the wild-type receptor, despite similar 
expression levels and affinity (Table 1). B. Time-course of 5-HT-induced PLC responses 
did not reveal a statistically significant difference between the PrC-5-HT2AR and the PrC-
[H452Y]5-HT2AR (means ± SEM, n=4, 2-Way ANOVA with Bonferroni post-hoc test). C. 
Time-course of PLD responses showed a statistically significant attenuation of 5-HT-
induced [3H]PtdBut production from 0-6 min in the PrC-[H452Y]5-HT2AR compared to the 
PrC-5-HT2AR (*, p<0.05, mean ± SEM, n=4, 2-Way ANOVA with Bonferroni post-hoc 
test).  
 
Fig. 2. Effect of dominant negative PLD1 or PLD2 constructs as well as selective PLD1 
or PLD2 inhibitors on 5-HT-induced [3H]PtdBut production responses at the PrC-5-HT2AR 
or the PrC-[H452Y]5-HT2AR in standard assay conditions. Catalytically inactive mutant 
PLD1 and the selective PLD1 inhibitor VU 0155069 (CAY 10593) at a concentration of 
0.5 µM caused statistically significant inhibition of responses to 3 µM 5-HT (**, p<0.01 
ANOVA with Dunnett’s post-hoc test) similarly at both the PrC-5-HT2AR and the PrC-
[H452Y]5-HT2AR (n=5 in each case). Catalytically inactive PLD2 or the selective PLD2 
inhibitor BML 280 at a concentration of 5 µM had no discernible effect.  
 
Fig.3. Effect of transfected additional wild-type PLD1 on 5-HT-induced [3H]PtdBut 
responses of the PrC-5-HT2AR and the PrC-[H452Y]5-HT2AR. Responses to 5-HT (0.3 
nM - 3µM) were measured in duplicate in 5 separate experiments for the PrC-5-HT2AR 
and the PrC-[H452Y]5-HT2AR in cells co-transfected with empty vector pcDNA3.1 or 
wild-type HA-PLD1. Data are plotted as the overall mean ± SEM values from each 
composite data set (n=5). Individual data sets were fitted by non-linear regression and 
the curve parameters are displayed and statistically evaluated in Table 2. Additional wild-
type PLD1 amplified [3H]PtdBut production responses at both the PrC-5-HT2AR and its 
H452Y variant but the degree of amplification was notably greater at the wild-type 
receptor. 
 
Fig.4. Specific association of PLD1 with the PrC-5-HT2AR in co-immunoprecipitation and 
GST-fusion protein binding experiments is reduced in the H452Y variant. A. COS7 cells 
co-transfected with either the PrC-5-HT2AR or the PrC-[H452Y]5-HT2AR and HA-PLD1 
were solubilised and PrC-tag-containing proteins were pulled down with a specific 
mouse monoclonal antibody (HPC4), or non-immune IgG for controls, together with 
Protein G-Sepharose beads. Captured proteins were separated by SDS-PAGE and blots 
were probed for PrC and HA tag immunoreactivity. Despite similar input levels of PrC-
tagged receptors and HA-PLD1, the amount of HA-PLD1 specifically captured in 
association with the H452Y variant receptor was clearly reduced compared to the wild-
type PrC-5-HT2AR. The double-ended arrow indicates that the HA-PLD1 lysate blot 
images for lanes 1 and 2 apply similarly to lanes 3 and 4 as each lysate was split 
between PrC-tag pulldown and NI-IgG control procedures. B. GST-fusion protein 
constructs of the carboxy-terminal tail domain of wild-type or H452Y variant receptors 
(residues 376-471) or GST alone were attached to glutathione-Sepharose beads and 
incubated with extracts of COS7 cells expressing HA-PLD1 or ARF1-HA. Despite similar 
input levels of constructs and similar binding of ARF1-HA, the H452Y variant receptor 
construct clearly bound lower levels of HA-PLD1 than the wild-type.  
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Fig. 5. Effects of N-myristoylated (cell-permeable) blocking peptides spanning different 
segments of the receptor’s distal carboxy-terminal tail domain on PLC and PLD 
responses of COS7 cells expressing the PrC-5-HT2AR. 5-HT (3 µM)-induced [3H]InsP 
and [3H]PtdBut production were measured in cells using the standard assay protocols 
after 15 min pre-incubation with the different peptides at a concentration of 50 µM. Data 
are shown as mean ± SEM values from 5 separate experiments in each case. The 
peptide covering residues 450-460 (which encompasses residue 452) caused a clear 
and selective reduction in PLD but not PLC responses (** p<0.01, by ANOVA with 
Dunnett’s post-hoc test). Neither the residue 439-449 peptide nor the residue 461-471 
peptide had any discernible effect.  
 
Fig. 6. Effects of 5-HT2AR antagonist, PLD inhibitors and N-myristoylated blocking 
peptides on 5-HT2AR agonist-induced PLD signalling and proliferation of MCF-7 cells. 
A. [3H]PtdBut production responses induced by 3 µM (R)-DOI were significantly 
inhibited by the selective 5-HT2AR antagonist M100709 (200 nM) or the selective 
PLD1 inhibitors VU 0155069 (0.5 µM) and VU 0359595 (50 nM) but not by the 
selective PLD2 inhibitor BML 280 (5 µM); means ± SEM, n=4, *p<0.05 or **p<0.01 by 
ANOVA with Dunnett’s post-hoc test. B. [3H]PtdBut production responses induced by 
3 µM (R)-DOI were significantly inhibited by the N-myristoylated blocking peptide 
mimicking 5-HT2AR residues 450-460 but not those covering residues 439-449 or 
461-471 (50 µM with 15 min pre-incubation); means ± SEM, n=4, *p<0.05 by ANOVA 
with Dunnett’s post-hoc test. C. (R)-DOI (3 µM)-induced increases in Alamar Blue 
fluorescence of MCF-7 cells, reflecting additional cell proliferation over 48 h 
incubation with the 5-HT2AR agonist were significantly inhibited by M100907 (200 
nM), VU 0359595 (50 nM) and the N-myristoylated peptide for residues 450-460 but 
not those for residues 439-449 or 461-471 (50 µM). Values are means ± SEM, n=4, * 
indicates p<0.05 by ANOVA with Dunnett’s post-hoc test. Under the present 
conditions the blockers had no significant effect on proliferation in the absence of 5-
HT2AR agonist. 
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Fig. 2. 
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Fig. 3. 
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Fig. 4. 
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Fig. 5. 
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Fig. 6. 
 
 
	  
